

# SCIENTIFIC PROGRAM



## THURSDAY, FEBRUARY 6

13:30–16:45 **Pre–Meeting workshops**

See program at page 9

17:00–18:00 **Satellite Symposia**

See program at page 12

18:15 **Welcome from the World Scleroderma Foundation** LEPTIS MAGNA ROOM

18:30 **Welcome from the Patron of the World Scleroderma Foundation** LEPTIS MAGNA ROOM  
The impact of scleroderma on a creative genius  
**A. Klee (CH)**

18.45–19.00 **Welcome from the Patients' Representative** LEPTIS MAGNA ROOM  
The Patients' Perspective  
**A Kennedy (IRL), President of FESCA**

19:00–19:40 **Opening Lectures** LEPTIS MAGNA ROOM  
**Two-years in Review-What's new since Madrid: the Cutting Edge**  
Chairpersons: **C Black (UK), F Wollheim (S)**

19:00 The clinical overview  
**M Matucci-Cerinic (I)**

19:20 The basic and translational I overview  
**J Varga (USA)**

19:40 **Rome Video**

20:00 **Light welcome cocktail**

THURSDAY, FEBRUARY 6  
FRIDAY, FEBRUARY 7

## SCIENTIFIC PROGRAM

### FRIDAY, FEBRUARY 7

FRIDAY, FEBRUARY 7

08:00–09:20 **Session 1** LEPTIS MAGNA ROOM  
**Management and assessment of newly diagnosed SSc**  
**Chairpersons: J van Laar (UK), N Damjanov (SR)**

08:00 What to do for a patient with newly diagnosed SSc  
 – How to assess a patient with new onset of possible systemic sclerosis  
 – What are the standard of care tests in early SSc patient  
 – What are the baseline factors of poor prognosis in very early and early SSc  
**P Clements (USA)**

**Chairpersons: F Van den Hoogen (NL), S Johnsson (CAN)**

08:20 NEW EULAR/ACR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN CLINICAL PRACTICE  
**O Distler et al (CH)**

08:30 2013 CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS AN AMERICAN COLLEGE OF RHEUMATOLOGY/EUROPEAN LEAGUE AGAINST RHEUMATISM COLLABORATIVE INITIATIVE.  
**J Pope et al (CAN)**

08:40 PERFORMANCE OF THE OLD 1980 ACR AND THE NEW ACR–EULAR SYSTEMIC SCLEROSIS (SSC) CLASSIFICATION CRITERIA IN PATIENTS WITH LIMITED CUTANEOUS SSC  
**P Carreira et al (E)**

08:50 EARLY ACCRUAL OF ORGAN DAMAGE IN SCLERODERMA: RATIONALE FOR DERIVATION AND VALIDATION OF A DISEASE DAMAGE INDEX IN SYSTEMIC SCLEROSIS  
**T Tay et al (AUS)**

09:00 PERFORMANCE OF THE 2013 ACR/EULAR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN A SINGLE CENTER SETTING  
**R Dobrota et al (R)**

09:10 SSC INTRINSIC SUBSET CLASSIFICATION IN PATIENTS THAT DEMONSTRATE CLINICAL IMPROVEMENT DURING TREATMENT  
**M Whitfield et al (USA)**

09:20–10:10 **Session 2** LEPTIS MAGNA ROOM  
**Miscellaneous and differential diagnosis of SSc**  
**Chairpersons: U Walker (CH), R Silver (USA)**

09:20 How to differentiate SSc from scleroderma-like disorder?  
 – Criteria for very early and early diagnosis of SSc  
 – Differential diagnoses to be presented including IgG4 syndromes, Shulman, nephrogenic fibrosis, borreliosis  
**A Tyndall (CH)**

09:40 GENDER EFFECTS ON SYSTEMIC SCLEROSIS PHENOTYPE: A LONGITUDINAL EUSTAR STUDY BASED ON MORE THAN 10 000 PATIENTS  
**M Elhai et al (F)**

09:50 EPIDEMIOLOGY OF CANCER IN SYSTEMIC SCLEROSIS. SYSTEMATIC REVIEW AND META-ANALYSIS OF CANCER INCIDENCE, PREDICTORS AND MORTALITY  
**S Johnson et al (CAN)**

10:00 JOINT AND TENDON INVOLVEMENT PREDICT SEVERE DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS: A EUSTAR PROSPECTIVE STUDY  
**J Avouac et al (F)**

*10:10–10:30 COFFEE BREAK*

## SCIENTIFIC PROGRAM

10:30–11:00 **Session 3** LEPTIS MAGNA ROOM  
**The great debate**  
 Chairpersons: R Giacomelli (I), B Maurer (CH)

The place of Corticosteroids in SSc  
**T Medsger (USA), J Seibold (USA)**

11:00–12:00 **Poster tours**  
**Clinical**  
 Poster tour 1: Raynaud & Ulcers - **V Ricciari (I)**  
 PS01 to PS06

Poster tour 2: Raynaud & Ulcers - **E Rosato (I)**  
 PS07 to PS12

Poster tour 3: Pulmonary / Interstitial Lung  
 Disease - **I H Tarner (D)**  
 PS13 to PS19

Poster tour 4: Pulmonary Arterial Hypertension  
**D Launay (F)**  
 PS20 to PS27

Poster tour 5: Cardiac - **A Vacca (I)**  
 PS28 to PS34

Poster tour 6: Outcomes, quality of life,  
 psychological & social - **P Carreira (E)**  
 PS35 to PS41

Poster tour 7: Imaging - **F Cozzi (I)**  
 PS42 to PS48

Poster tour 8: Therapy/Miscellaneous - **A Sulli (I)**  
 PS49 to PS55

Poster tour 9: Musculoskeletal system  
 & rehabilitation - **P Ostojic (SRB)**  
 PS56 to PS61

Poster tour 10: Upper and Lower Gastrointestinal/  
 nutrition - **T Minier (H)**  
 PS62 to PS68

Poster tour 11: Pregnancy & sexual problems  
**L Saketkoo (USA)**  
 PS69 to PS73

Poster tour 12: Therapy - **S Bellando-Randone (I)**  
 PS74 to PS82

**Basic**  
 Poster tour 13: Pathogenesis - **M Manetti (I)**  
 PS83 to PS94

Poster tour 14: Pathogenesis - **GL Moroncini (I)**  
 PS95 to PS102

Poster tour 15: Pathogenesis - **S Assassi (USA)**  
 PS103 to PS111

12:00–13:30 **Satellite Symposia**  
 See program at page 11

13:30–14:30 **Working lunch** LEVEL –2

14:30–15:30 **Satellite Symposia**  
 See program at page 11

15:30–16:40 **Concurrent Sessions**

15:30–16:30 **Concurrent Session 4** LEPTIS MAGNA ROOM  
**An integrated approach to**  
**gastro–intestinal involvement**  
 Chairpersons: A Herrick (UK), T Frech (USA)

15:30 GI: How to evaluate, diagnose and treat upper and  
 lower GI involvement  
**U Mueller–Ladner (D)**

FRIDAY, FEBRUARY 7

## SCIENTIFIC PROGRAM

- 15:50 New therapeutic approaches  
**C Murray (UK)**
- 16:10 MORTALITY, RECURRENCE, AND HOSPITAL COURSE OF PATIENTS WITH SYSTEMIC SCLEROSIS RELATED ACUTE INTESTINAL PSEUDO-OBSTRUCTION  
**C Derk et al (USA)**
- 16:20 PREVALENCE, CORRELATES AND OUTCOMES OF GASTRIC ANTRAL VASCULAR ECTASIA IN SYSTEMIC SCLEROSIS: A EUSTAR CASE-CONTROL STUDY  
**E Ghrenassia et al (F)**
- 15:30–16:40 **Concurrent Session 5** MASSALIA ROOM  
**Links to inflammation, immunity and vascular disease**  
**Chairpersons: J Distler (D), D Abraham (UK)**
- 15:30 Immunological mechanisms of fibrosis  
**T Wynn (USA)**
- 15:50 PIGMENT EPITHELIUM DERIVED FACTOR SECRETED BY SSC FIBROBLASTS INHIBITS ANGIO AND VASCULOGENESIS IN VITRO  
**V Liakouli et al (I)**
- 16:00 SCLERODERMA DERMAL FIBROBLASTS OVEREXPRESS VASCULAR ENDOTHELIAL GROWTH FACTOR DUE TO AUTOCRINE TRANSFORMING GROWTH FACTOR BETA SIGNALING  
**I Kajihara et al (JPN)**
- 16:10 IL 6 TRANS -SIGNALLING AND CCL2 CO -REGULATE FIBROBLAST DEPENDENT TRANS -ENDOTHELIAL MIGRATION OF MONONUCLEAR CELLS AND FIBROTIC RESPONSE IN SCLERODERMA  
**R Alade et al (UK)**
- 16:20 THE GLOBAL MICRORNA PROFILE OF SKIN IN SYSTEMIC SCLEROSIS  
**G Salazar et al (USA)**
- 16:30 THE PRESENCE OF A COLD TEMPERATURE SENSOR IN THE VASCULAR ENDOTHELIUM: ENHANCED EXPRESSION IN SSC SKIN AND ENDOTHELIAL CELLS DYSFUNCTION AFTER ACTIVATION  
**B Kahaleh et al (USA)**
- 16:40–16:55 *COFFEE BREAK*
- 16:55–18:15 **Concurrent Sessions**
- 16:55–17:25 **Concurrent Session 6** LEPTIS MAGNA ROOM  
**Biologics and novel therapies in SSc**  
**Chairpersons: R Simms (USA), C Beyer (D)**
- 16:55 Use of biologics in SSc-indications and future perspective  
– An update on the use of biologics in SSc  
– Benefit/risk ratio of the main molecules  
– Upcoming trials  
**Y Allanore (F)**
- 17:25–17:55 **Concurrent Session 7** LEPTIS MAGNA ROOM  
**Treatment and DMARDS in SSc**  
**Chairpersons: P Sampaio Barros (BRA), M Kuwana (JPN)**
- 17:25 How to treat rapidly progressive SSc  
**C Denton (UK)**
- 16:55–18:15 **Concurrent Session 8** MASSALIA ROOM  
**Mechanism of fibrosis**  
**Chairpersons: A Gabrielli (I), R Lafyatis (USA)**
- 16:55 Biomechanical Signaling of Myofibroblast Activation  
**V Thannickal (USA)**
- 17:15 SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) REGULATES TRANSFORMING GROWTH FACTOR-BETA INDUCED FIBROSIS IN SYSTEMIC SCLEROSIS  
**B Sumova et al (D)**

## SCIENTIFIC PROGRAM

17:25 INVESTIGATING THE ROLE OF MYOCARDIN RELATED  
TRANSCRIPTION FACTOR (MRTF) IN SYSTEMIC SCLEROSIS  
**X Shiwen et al (UK)**

17:35 EPHRIN B2 IS OVEREXPRESSED IN HUMAN  
SCLERODERMA SKIN AND MEDIATES FIBROBLAST TO  
MYOFIBROBLAST DIFFERENTIATION, AND INDUCES  
FIBROSIS IN MICE  
**M Kapoor et al (CAN)**

17:45 EXPERIMENTAL RENAL INJURY IN A TGF $\beta$  DEPENDENT  
MOUSE MODEL OF SCLERODERMA  
**E Derrett-Smith et al (UK)**

17:55 DIRECT THROMBIN INHIBITOR DABIGATRAN ETEXILATE  
PROTECTS ALVEOLAR EPITHELIAL CELLS FROM  
APOPTOSIS IN A BLEOMYCIN MODEL OF  
SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE  
**G Bogatkevich et al (USA)**

18:05 STIMULATION OF THE SOLUBLE GUANYLATE CYCLASE  
(SGC) INHIBITS DERMAL FIBROSIS BY BLOCKING  
NON-CANONICAL TGF- $\beta$ -SIGNALING  
**C Beyer et al (D)**

Approach to Ulcer Therapy  
**M Vonk (NL) & S Guiducci (I)**

HAMA ROOM

Approach to Therapy of Tendon  
& Joint Inflammation  
**M Mayes (USA)**

MILETO ROOM

Approach to GI management  
**Fox (CH)**

SABRATHA ROOM

09:00–09:40 **Session 10** LEPTIS MAGNA ROOM  
**Cardiovascular involvement**  
Chairpersons: **M Inanc (TR), A Vacca (I)**

09:00 Conduction and Rhythm defects in scleroderma  
**C Meune (F)**

09:20 IMPROVEMENT OF DIGITAL ULCERATIVE DISEASE IN  
PATIENTS WITH SYSTEMIC SCLEROSIS IS ASSOCIATED  
WITH BETTER FUNCTIONAL PROGNOSIS  
**L Mouthon et al (F)**

09:30 PREDICTION OF CARDIAC AND VASCULAR EVENTS IN  
SYSTEMIC SCLEROSIS: INPUT FROM ENDOTHELIN -1  
TYPE A RECEPTOR ANTIBODIES  
**J Avouac et al (F)**

09:40–10:30 **Session 11** LEPTIS MAGNA ROOM  
**Interstitial lung disease**  
Chairpersons: **B Kahaleh (USA), O Kowal Bielecka (Pl)**

09:40 SSc-ILD: Who to treat and how to treat?  
– Discuss natural history and disease progression  
in ILD  
– How to identify patients who require  
immuno suppressive therapy  
– Efficient drugs and predictors of response  
**D. Khanna (USA)**

## SATURDAY, FEBRUARY 8

08:00–09:00 **Session 9**  
**Meet the Professors session**  
See information at page: 42

Approach to SSc-Related  
Cardiac Disease  
**L Czirjak (H) & Y Allanore (F)**

CESAREA ROOM

Approach to Kidney Management  
**L Guillevin (F) & C Denton (UK)**

EFESO ROOM

## SCIENTIFIC PROGRAM

- 10:00 PROGRESSIVE DETERIORATION OF PATIENTS WITH SCLERODERMA WITH PULMONARY INVOLVEMENT: 11-YEAR OUTCOMES FROM THE SCLERODERMA LUNG STUDY (SLS1)  
**K Sullivan et al (USA)**
- 10:10 SURVIVAL AFTER LUNG TRANSPLANTATION IN SYSTEMIC SCLEROSIS. A SYSTEMATIC REVIEW.  
**S Johnson et al (CAN)**
- 10:20 GENETIC MARKERS OF SUSCEPTIBILITY AND INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS PATIENTS: AN IMMUNOCHIP STUDY  
**L Bossini-Castillo et al (E)**
- 10:30–10:45 *COFFEE BREAK*
- 10:45–11:55 **Session 12** LEPTIS MAGNA ROOM  
**Pulmonary Arterial Hypertension**  
Chairpersons: V Steen (USA), E Hachulla (F)
- 10:45 PAH: How to make the right diagnosis at the right time  
– Risk factors and predictors of PAH  
– Criteria guiding the clinician to refer the patient for catheterisation  
– How to interpret catheterisation  
**O Distler (CH)**  
  
Chairpersons: M Hinchcliff (USA), L Chung (USA)
- 11:05 CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY HYPERTENSION AND A PULMONARY CAPILLARY WEDGE PRESSURE >15 IN THE PHAROS REGISTRY  
**L Saketkoo et al (USA)**
- 11:15 RECOMMENDATIONS FOR SCREENING AND DETECTION OF CONNECTIVE-TISSUE DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION  
**D Khanna et al (USA)**
- 11:25 A COMPARISON OF THE PREDICTIVE ACCURACY OF THREE SCREENING MODELS (DETECT V. ESC/ERS V. ASIG) FOR PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS  
**Y J Hao et al (AUS)**
- 11:35 CLINICAL SUBTYPE AND AUTOANTIBODIES BOTH HELP PREDICT PULMONARY ARTERIAL HYPERTENSION BUT AUTOANTIBODIES ARE STRONGER PREDICTORS OF DEVELOPING SECONDARY PULMONARY HYPERTENSION  
**R Domsic et al (USA)**
- 11:45 PROGNOSTIC VALUE OF NT-PROBNP IN SYSTEMIC SCLEROSIS PATIENTS WITHOUT PULMONARY HYPERTENSION  
**M Antivalle et al (I)**
- 11:55–12:10 **Special Lecture** LEPTIS MAGNA ROOM  
Chairpersons: F Del Galdo (UK), G Riemekasten (D)  
  
DeSSciper, a jump in the future!  
**U Mueller-Ladner (D)**
- 12:10–12:30 **Summary of the congress** LEPTIS MAGNA ROOM  
Chairperson: L Guillevin (F)  
  
Highlites of the World Scleroderma Congress, 2014  
**D Furst (USA)**
- 12:30–13:00 **Closing Ceremony** LEPTIS MAGNA ROOM